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baseline and follow ups (experienced-Infliximab group, EIG) and those who were
not treated with Infliximab at baseline but went on Infliximab treatment at the
followups (new-Infliximab group, NIG). RESULTS:Of the 427 RApatients, 48 (11.2%)
used Infliximab before, 83%were female, and the average agewas 45 years old. The
average duration of RA was 6 years, with almost 40% patients suffering RA more
than 5 years. At baseline, the mean scores reported from the patients in EIG were:
morning stiffness 31min, pain 45, HAQ 0.65, MCS 47 and PCS 38, which were all
significantly better than patients in NIG. After 14 weeks Infliximab treatment, NIG
patients improved significantly in morning stiffness (-55.6min), pain (-38.5), HAQ
(-0.6), MCS (-16.2) and PCS (-15.6) than baseline (all P0.0001). CONCLUSIONS: RA
patients using Infliximab have better quality of life and daily function activities
than those not using Infliximab before. Our findings also indicate that, it is essen-
tial to continue or initiate treatment with Infliximab to improve outcomes and
quality of life in RA patients in China.
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OBJECTIVES: To report results of HRQOL in Chinese patients with rheumatoid
arthritis (RA) and ankylosing spondylitis (AS). METHODS: Adult patients 18yrs
diagnosed with RA or AS were recruited through referrals by physicians in 11
cities(tier 1 and tier 2 level) in China: Beijing, Shanghai, Guangzhou, Tianjin, Wu-
han, Nanjing, Hangzhou, Shenyang, Chengdu, Taiyuan, and Shijiazhuang. Patients
should have worked and stayed in the city 1yr. Disease severity was classified as
mild, moderate and severe based on physician’s subjective assessment. A Chinese
version of the Short-Form(SF)-36 (version 2) was completed by patients. A norm-
based scoring system developed from Chinese population(Hong Kong) was used to
derive 8 subscales: physical functioning(PF), role-physical(RP), bodily pain(BP), gen-
eral health(GH), vitality(VT), social functioning(SF), role-emotional(RE), andmental
health(MH); and physical and mental component summary(PCS and MCS) scores.
Each score ranges from 0 to 100 with higher scores representing better HRQL.
Descriptive statistics are presented. RESULTS: Adult patients with RA(N250, 94
male and 156 female) and AS(N150, 81 male, 69 female) were enrolled and com-
pleted the SF-36 questionnaire. Overall, patients demonstrated low scores (50) in
all 8 SF-36 subscales, especially in PF (31.316.7 vs 32.415.1), BP(34.79.4 vs
35.08.1) and SF(33.613.3 vs 33.012.8), for RA vs AS, respectively. The PCS and
MCS scores were 35.510.4 and 45.310.4, respectively, in AS patients and
34.711.7 and 46.39.6, respectively, in RA patients. These scores decreased with
increase in disease severity and age, but remained consistent with no significant
differences between men and female. CONCLUSIONS: SF-36 scores in Chinese pa-
tients with RA or AS were lower compared to the general Chinese population with
chronic diseases including cardiovascular disease and diabetes, indicating major
impairment in HRQOL.
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OBJECTIVES: Cost-utility analysis is increasingly important to market access deci-
sions in a growing number of countries including Australia. The ability to attach
utility values to health states is an essential component of cost-utility analysis. The
primary aim of this review was to identify appropriate utility weights in rheuma-
toid arthritis (RA) in Australia. The review also aimed to evaluate existing quality of
life (QoL) measures used in RA and identify the key issues associated with the use
of these measures. METHODS: Systematic methods were used to search the Eng-
lish language literature for studies reporting health-related utilities for RA. The
literature search covered a wide range of electronic databases (EMBASE, Medline,
Cochrane Library), and included literature from the inception of database to Janu-
ary 2012. RESULTS: The search identified 28 studies: 2 from Australia and 26 from
other countries. Both Australian studies reported mean EQ-5D utility values for
Australian patients with RA. One of the Australian studies also found that the HAQ
scores explained more of the variance in the HUI3-derived than EQ-5D-derived
utility weights, and that RA-affected joint counts had negligible explanatory power
for patient utility. Review of the other 26 studies found that a variety of QoL instru-
ments were used. All instruments were found to be valid measures for QoL in
patients with RA and appeared to adequately discriminate across levels of RA
severity. Nevertheless, each instrument revealed strengths and weaknesses,
which prevented the recommendation of one instrument in favour of the other.
CONCLUSIONS: This review of utility weights for RA revealed a high level of un-
certainty about the evidence base that informs cost-utility analyses in this disease
area. There is no conclusive evidence to date as towhichmeasure is the best for use
in RA.
NEUROLOGICAL DISORDERS - Clinical Outcomes Studies
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OBJECTIVES: Despite the fact that non-benzodiazepine hypnotics (Z-drugs) are
beneficial for the short-termmanagement of insomnia, it is inconclusive about the
risk and benefit ratios of long-term use. The aim of this study was to examine the
medication use patterns of Z-drugs and its prescribers in a 2000-bedmedical center
in Taiwan. METHODS: We conducted the medication use evaluation study using
China Medical University Hospital (CMUH) in-house databases. During the whole
year of 2011, those CMUHoutpatients ever prescribedwith zolpidem and zopiclone
were of interest. Their prescription prevalence rate of Z-drugs, its average number
of defined daily dose (DDD), prescriber specialties and demographic characteristics
were examined using descriptive analyses. RESULTS: In 2011, 2,261 and 2,885 pa-
tients were ever prescribed with at least one prescription with zolpidem and zopi-
clone, respectively, in the outpatient units in CMUH. While more female were
prescribed with Z-drugs, 40% of zolpidem users and 32% of zopiclone users were
elderly. Within one year period, the average prescription number of zolpidem and
zolpiclone were 5.474.78 and 4.34.38, respectively. While the average durations
for each prescription were 257 days for zolpidem and 238 days for zolpiclone,
respectively. 25% of zolpidem users and zolpiclone users were prescribed 9 to 43
times and 6 to 52 times, respectively. The top three prescribers were neurologist,
cardiologist, and psychiatrist, which in total had accounted for 63.01% and 46.96%
of zolpidem and zolpiclone prescriber specialties, respectively. CONCLUSIONS:
There is a tendency to have long-termuse of zolpidemand zopiclone among CMUH
outpatients. Those common prescribers of Z-drugs should be warranted for its
consequences of long-term use, especially among the elderly.
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OBJECTIVES: Despite global advancements in disease reporting, the epidemiology
of multiple sclerosis (MS) in Asia is not well reported. MS rates in Asia are low
compared to Europe and North America, but are now thought to be increasing.
Globally, themedian prevalence ofMS is 30/100,000. Our goal is a systematic search
of epidemiologic studies of MS in Asia to determine accurate epidemiologic and
treatment cost estimates. METHODS: This systematic review examined articles
published in English over 20 years using MESH terms: MS, incidence, prevalence,
mortality and costs in any Asian country. Articles with evidence from population-
based samples, based on clinically-defined or laboratory supported MS (e.g., Mc-
Donald criteria) diagnoses, and from major Asian countries were retained. Costs
were the 2008 estimates from the Global Economic Impact of MS. RESULTS: As in
other continents, prevalence in Asia is higher in women than men. In the largest
country, China, prevalence rates of MS are low (1-2/100,000). In Northern Japan, a
much higher prevalence (8.6/100,000) was reported in 2002, an increase from 2.5 in
1975. In Korea, with a population density similar to China, the prevalence was
3.5/100,000, similar to the 3.0/100,000 in Taiwan (2005). Based on an annual cost per
patient of $41,335 (USD international), 2008 estimated costs in China due to MS
exceed $1 billion. In Japan, with 10 times fewer people, the costs exceed $452
million. CONCLUSIONS:Data frommany Asian countries is limited and often from
case-series designed to review clinical characteristics. Larger epidemiological and
cost-based studies in various populations are still needed. Recent evidence sug-
gests a higher prevalence than previously thought, possibly a result of better as-
certainment driven by increased diagnostic awareness. This review supports the
development of effective medications and additional research to better under-
stand the unmet medical need and economic burden driven by MS in Asia.
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OBJECTIVES: Prolonged-release (PR) fampridine is a first-in-class treatment for the
management of walking disability in multiple sclerosis (MS). The purpose of this
study was to evaluate the budget impact of PR-fampridine introduction in the
treatment of MS patients with an Expanded Disability Severity Scale (EDSS) score
between 4.0 and 7.0 in Taiwan.METHODS: A budget impact model was developed
with amonthly cycle Markov-chain to evaluate the cost implications of PR-fampri-
dine use to the Taiwan health care payer. All costs in themodel were sourced from
the Taiwan National Health Insurance formulary and are presented in Taiwan
dollars (NT$). Response rates of 35% and 43%, derived frompivotal Phase III trials of
PR-fampridine, were applied. The budget impact was calculated for a 5-year time
horizon. The base case analysis included the treatment costs of PR-fampridine
only. Sensitivity analyseswere conducted on the impact of PR-fampridine on direct
costs and on market share. RESULTS: For the year 2012, the model estimated 79
patients with EDSS between 4.0 and 7.0 and walking impairment eligible for PR-
fampridine treatment. Budget impact after the introduction of PR-fampridine us-
ing a patient response rate of 35% was NT$241,000 rising to NT$3,225,000 over the
5-year time horizon. Applying a 43% response rate resulted in a budget impact of
NT$285,000 in 2012which equates to a 3.61% increase in spending. CONCLUSIONS:
Walking difficulty is one of themost commonly reported disabilities inMS patients
and PR-fampridine is the only medication indicated for symptom alleviation. The
introduction of PR-fampridine leads to a manageable budget impact in Taiwan as
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well as reduces the debilitating burden of walking disability in MS patients. Future
studies are required to investigate the direct cost offsets as a result of treatment
with PR-fampridine.
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OBJECTIVES: To estimate the costs of management of children with structural-
metabolic epilepsy and to determine the cost-driving factors in the selected
population. METHODS: This was a retrospective annual prevalence-based study
that included patients who attended a paediatric neurology clinic in a tertiary
referral centre inMalaysia. The total costs of epilepsymanagementwere estimated
from the provider (i.e., hospital) perspective, using a bottom-up,microcosting anal-
ysis. Medical chart/billing data (i.e., case reports) obtained from the hospital (i.e.,
provider) were collected to determine the resources used. Prices or cost data were
standardised for the year 2010. RESULTS: Themost expensive item in the costs list
was antiepileptic drugs, whereas ultrasound examination represented the cheap-
est item. Hospitalisation and the use of non-antiepileptic drugs were the second
and third most costly items, respectively. The cost of therapeutic drug monitoring
comprised only a small proportion of the total annual expenditure. None of the
demographic variables (i.e., gender, race, and age) significantly impacted the an-
nual cost of epilepsy management. Similarly, child development and seizure type
were also not associatedwith the cost ofmanagement. On the other hand, children
who received polytherapy treatment, therapeutic drug monitoring, or adjuvant
therapy with new antiepileptic drugs represented high-cost groups of patients.
Moreover, the total annual cost of epilepsymanagement positively correlated with
seizure frequency. CONCLUSIONS: This investigation was the first cost analysis
study of epilepsy inMalaysia. The total annual cost ofmanagement for 120 patients
with structural-metabolic epilepsy was RM 202,816 (i.e., RM 1690.13 per patient per
year). The study findings highlight the importance of optimizing seizure control in
reducing the cost of management.
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OBJECTIVES:With the ageing of the population, dementia has emerged as a major
public health and economic burden in industrialized countries. Our study aimed at
evaluating direct health care costs in a population of community-dwelling elderly
patients with treated dementia and at comparing such costs with those among
non-demented elderly.METHODS: A retrospective cohort study was conducted in
the community-dwelling elderly population of Quebec using the RAMQ adminis-
trative claims databases (medical services and prescribed medications) and the
Med-Echo hospital discharge database. Patients aged 66 and over, who received at
least one dispensing for a cholinesterase inhibitor (ChI) (donepezil, rivastigmine, or
galantamine) between January 1, 2000 and December 31, 2009 were included in the
cohort of patients with dementia (n37,138). The date of entry in the cohort (index
date) was the date of first dispensing for a ChI during the study period. The com-
parison cohort included elderly patients with no diagnosis of dementia matched
with a 1:1 ratio on age group, gender, and index date. Economic variables included
direct costs of prescribed medications, medical services, hospitalizations and
institutionalization. RESULTS: Overall, our study showed that, at 1 year follow-up,
total health care costs are higher among patients with dementia than among non-
demented elderly (CAD$8360 compared to CAD$5368). Costs associated with ChI
treatment ($1285) andhospitalization ($1103) accounted for the greatest proportion
of the cost difference between the two populations. Over a five-year period, total
health care costswere $38,200 ( $62,180) in the cohortwith dementia compared to
$19,042 ( $31,346) in non-demented elderly. At this time, costs associateed with
institutionalization also contributed significantly to the difference.
CONCLUSIONS: Dementia is an important socioeconomic burden. Despite the
availability of treatments for dementia and the high death rate over a 5-year period,
costs associated with hospitalization and institutionalization increase exponen-
tially, resulting in a major public health burden.
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OBJECTIVES: Patients with neurological conditions such as multiple sclerosis or
spinal cord injurymay experience urinary incontinence resulting from neurogenic
detrusor overactivity (NDO). In addition to reduced quality of life, uncontrolled
NDO can have pathophysiological consequences including urological disorders
and renal failure. Studies have shown that a substantial proportion ofNDOpatients
are inadequately managed by conservative treatments, which include lifestyle
modifications and oral anticholinergicmedication. Recent clinical trials have dem-
onstrated that botulinum toxin type A injections significantly reduce incontinence
frequency. The objective of this study is to examine the cost reductions following
treatment with botulinum toxin type A in NDO patients, in the context of the
Australian health care system. METHODS: Based on data from two Phase III dou-
ble-blinded randomised placebo-controlled trials in NDO patients, a semi-Markov
model was developed to compare treatment with 200U of botulinum toxin type A
versus best supportive care (BSC: pads, catheters, and the option of anticholin-
ergics). Systematic literature searches and a survey of continence nurse practitio-
ners were conducted to source additional information (eg, natural history or re-
source utilisation of NDO patients). The costs considered in themodel include drug
costs, incontinence-related costs (eg, pads, catheterisation), and downstream
health care costs (eg, bladder augmentation surgery). RESULTS: Over a time hori-
zon of 5-years, compared to BSC, botulinum toxin type A treatment results in a
reduction in cost of incontinence pads ($2,445), catheterisation ($592), and a
modest reduction in general practitioner visits ($141) and the likelihood of un-
dergoing bladder augmentation surgery ($235). CONCLUSIONS: Botulinum toxin
typeA treatment is associatedwith cost reductions inNDOpatients and represents
a viable treatment option for NDO patients who are inadequately managed by oral
anticholinergics, and who may otherwise have to consider invasive surgical inter-
ventions.
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The costs of multiple sclerosis (MS) in China are not well known because of com-
paratively low prevalence rate and treatment complexity. OBJECTIVES: To assess
the treatments and costs of MS in China from social perspective by surveying both
patients and physicians.METHODS:Multi-center, questionnaire-based surveywas
conducted in major cities of China to collect health resource utilization, direct and
indirect costs related to MS. An Excel-based model was developed to estimate the
annual cost of MS in China by combining prevalence rate from systematic litera-
ture review, data from surveys and other published information. The costs ofMS in
China were estimated from patient and physician surveys separately and com-
pared with each other. RESULTS: A total of 110 relapsing-remitting multiple scle-
rosis (RRMS) patients and 5 physicians participated the survey. Patients (12.7% age
30; 55.4% age 30-50; and 31.9% age 50 years old) were assessed by Expanded
Disability Status Scale (EDSS) (36% mild; 51% moderate, and 13% sever). The total
cost from patient survey was USD 18,566 (1 USD 6.56 RMB, 2010-2011) (USD 13,265
direct cost and USD 5301 indirect cost) per person year. Total direct cost from
physician survey was USD 10,307 per year (USD 7,137 for medications). Annually
total cost of MS in China, using prevalence data from an epidemiology study, was
estimated to be USD 331.7 million (USD 245.2 million direct costs and USD 86.5
million indirect costs). CONCLUSIONS: The study shows that MS imposes a consid-
erable burden on Chinese patients, especially during disease diagnosis and relapse
periods. Unlike western countries, few patients in China take Disease Modified
Treatments (DMTs) because of the high out of pocket costs. The indirect costs ofMS
are significant and may increase in the near future, which will exacerbate the
burden on individual patients.
PND10
ECONOMIC EVALUATION OF INTERFERON âETA-1A VERSUS INTERFERON
âETA-1B IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS
(RRMS) IN IRAN
Golestani M1, Rasekh H1, Imani A2
1Shahid Beheshti Medical University, tehran, Iran, 2Tabriz Medical University, Tehran, Tehran,
Iran
OBJECTIVES: To evaluate the cost-effectiveness analysis of two Disease-modifying
drugs (DMD) used as first-line treatment of Relapsing Remitting Multiple Sclerosis
(RRMS): interferon IFN-1a IM injection (Avonex®) and IFN -1b SC injection (Be-
taferon®) from IranianMinistry of Health perspective.METHODS:A cost-effective-
ness analysis (CEA) was performed fromMinistry of Health (MoH). The outcome of
interest was number of relapses avoided. Costs were reported in 2011 USD. Costs
and outcomes were discounted at 5%. The time horizon was two years. All uncer-
tainties were tested via one-way sensitivity analyses. RESULTS: Total costs per
patient over the time horizon of a study were estimated at 39923, 47670 and 52045
USD for symptom management, IM IFN-1a and SC IFN-1b, respectively. The
incremental cost per relapse avoided was 25823 and 14965 USD for IM IFN-1a and
SC IFN-1b, respectively, compared with no active treatment (symptom manage-
ment). Results were sensitive to the discount rate, frequency of relapse and cost of
DMDs. CONCLUSIONS: The cost-effectiveness analysis determined that INF-1b
SC (Betaferon® ) was the best strategy of the two immunomodulatory therapies
used to treatment of patients experiencing an relapsing-remitting multiple sclero-
sis (RRMS) and resulted in better outcomes than symptom management alone.
Sensitivity analyses indicated that themodel was sensitive to changes in a number
of key parameters, and thus changes in these key parameters would likely influ-
ence the estimated cost-effectiveness results.
PND11
LACOSAMIDE FOR THE TREATMENT OF PARTIAL ONSET SEIZURES WITH OR
WITHOUT SECONDARY GENERALISATION: COST-EFFECTIVENESS ANALYSIS
ON TREATING PATIENTS WITH LACOSAMIDE IN COMBINATION WITH A NON-
SODIUM ANTI-EPILEPTIC MEDICATION
Makarounas-Kichmann K1, Kirchmann M2, Monin N3
1Monash University, FRANKSTON SOUTH, VIC, Australia, 2KMC Health Care, VIC, VIC,
Australia, 3UCB Pharmaceuticals, Malvern, VIC, Australia
A676 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 6 0 2 – A 6 8 1
